Rep. Gilbert Ray Cisneros, Jr. Sells Off Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). In a filing disclosed on November 18th, the Representative disclosed that they had sold between $1,001 and $15,000 in Supernus Pharmaceuticals stock on October 9th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of CommVault Systems (NASDAQ:CVLT) on 11/3/2025.
• Sold $1,001 – $15,000 in shares of The Descartes Systems Group (NASDAQ:DSGX) on 11/3/2025.
• Purchased $1,001 – $15,000 in shares of Cohen & Steers (NYSE:CNS) on 10/30/2025.
• Purchased $1,001 – $15,000 in shares of Credo Technology Group (NASDAQ:CRDO) on 10/30/2025.
• Sold $1,001 – $15,000 in shares of UFP Industries (NASDAQ:UFPI) on 10/30/2025.
• Purchased $1,001 – $15,000 in shares of Enerpac Tool Group (NYSE:EPAC) on 10/30/2025.
• Sold $1,001 – $15,000 in shares of Sterling Infrastructure (NASDAQ:STRL) on 10/30/2025.
• Purchased $1,001 – $15,000 in shares of Tencent (OTC:TCTZF) on 10/21/2025.
• Purchased $1,001 – $15,000 in shares of Mitsubishi Heavy Industries (OTCMKTS:MHVYF) on 10/21/2025.
• Purchased $1,001 – $15,000 in shares of Iberdrola (OTCMKTS:IBDSF) on 10/21/2025.

Supernus Pharmaceuticals Stock Performance

SUPN traded down $0.17 during trading on Monday, reaching $45.15. 815,205 shares of the company’s stock were exchanged, compared to its average volume of 697,077. The company’s fifty day moving average price is $48.50 and its 200-day moving average price is $40.50. The firm has a market capitalization of $2.59 billion, a PE ratio of 39.26 and a beta of 0.75. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $29.16 and a fifty-two week high of $57.65.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings results on Tuesday, November 4th. The specialty pharmaceutical company reported $0.46 earnings per share for the quarter, missing analysts’ consensus estimates of $0.82 by ($0.36). Supernus Pharmaceuticals had a net margin of 9.70% and a return on equity of 14.22%. The company had revenue of $170.00 million during the quarter, compared to analyst estimates of $175.82 million. During the same period last year, the company earned $0.69 EPS. The business’s revenue for the quarter was up 9.3% compared to the same quarter last year. Supernus Pharmaceuticals has set its FY 2025 guidance at EPS. Research analysts forecast that Supernus Pharmaceuticals, Inc. will post 2.38 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. CIBC Bancorp USA Inc. acquired a new stake in shares of Supernus Pharmaceuticals during the third quarter worth $275,000. Jacobs Levy Equity Management Inc. bought a new position in Supernus Pharmaceuticals during the 3rd quarter worth about $1,872,000. Caxton Associates LLP acquired a new stake in shares of Supernus Pharmaceuticals in the 3rd quarter valued at about $1,117,000. Woodline Partners LP lifted its holdings in shares of Supernus Pharmaceuticals by 63.5% in the third quarter. Woodline Partners LP now owns 1,263,811 shares of the specialty pharmaceutical company’s stock valued at $60,398,000 after purchasing an additional 490,835 shares in the last quarter. Finally, Public Employees Retirement System of Ohio boosted its position in shares of Supernus Pharmaceuticals by 2,742.0% during the third quarter. Public Employees Retirement System of Ohio now owns 16,967 shares of the specialty pharmaceutical company’s stock worth $811,000 after buying an additional 16,370 shares during the period.

Analysts Set New Price Targets

A number of equities analysts have issued reports on SUPN shares. Piper Sandler upgraded Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $40.00 to $65.00 in a report on Thursday, October 9th. Cantor Fitzgerald lifted their price objective on shares of Supernus Pharmaceuticals from $46.00 to $63.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 30th. TD Cowen upped their target price on shares of Supernus Pharmaceuticals from $45.00 to $60.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. Zacks Research upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, September 17th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Wednesday, November 19th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $63.25.

Insider Transactions at Supernus Pharmaceuticals

In other news, CEO Jack A. Khattar sold 59,900 shares of the firm’s stock in a transaction that occurred on Thursday, October 9th. The shares were sold at an average price of $50.57, for a total transaction of $3,029,143.00. Following the completion of the transaction, the chief executive officer directly owned 1,206,578 shares of the company’s stock, valued at $61,016,649.46. This trade represents a 4.73% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Frank Mottola sold 5,000 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $45.87, for a total transaction of $229,350.00. Following the completion of the sale, the senior vice president owned 15,496 shares in the company, valued at $710,801.52. This trade represents a 24.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 183,135 shares of company stock valued at $8,773,587. 8.80% of the stock is owned by corporate insiders.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.